Literature DB >> 1656866

Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy.

J M Diver1, T Schollaardt, H R Rabin, C Thorson, L E Bryan.   

Abstract

The mechanisms of persistence to ciprofloxacin in nine sets of Pseudomonas aeruginosa strains isolated during ciprofloxacin therapy of chronic lung infections in cystic fibrosis patients were studied. Low to moderate levels of ciprofloxacin resistance developed in each case. Each set of pretherapy ciprofloxacin-susceptible, during-therapy ciprofloxacin-resistant, and posttherapy ciprofloxacin-susceptible isolates were shown to be genotypically related by using a radiolabeled epidemiological gene probe. All ciprofloxacin-resistant isolates were found to have altered susceptibilities to both nalidixic acid and various chemically unrelated antibiotics. Analysis of possible resistance mechanisms showed that the strains had altered outer membrane protein or lipopolysaccharide profiles. Complementation of possible DNA gyrase mutations with a plasmid-borne, wild-type Escherichia coli gyrA gene indicated that altered DNA gyrase was at least partly responsible for ciprofloxacin resistance in all strains tested. Attempts to generate ciprofloxacin-susceptible revertants in vitro showed that in some strains reversion was rapid in the absence of ciprofloxacin, while in other strains it was not possible to generate revertants. These data indicate that persistence of Pseudomonas aeruginosa to ciprofloxacin involves changes in DNA gyrase and is associated with pleiotropic changes in outer membrane proteins and lipopolysaccharide.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1656866      PMCID: PMC245215          DOI: 10.1128/AAC.35.8.1538

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  45 in total

1.  PREPARATION OF TRANSFORMING DEOXYRIBONUCLEIC ACID BY PHENOL TREATMENT.

Authors:  H SAITO; K I MIURA
Journal:  Biochim Biophys Acta       Date:  1963-08-20

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Penetration of beta-lactams through Pseudomonas aeruginosa porin channels.

Authors:  A J Godfrey; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1987-08       Impact factor: 5.191

4.  Identification of porins in the outer membrane of Pseudomonas aeruginosa that form small diffusion pores.

Authors:  E Yoshihara; T Nakae
Journal:  J Biol Chem       Date:  1989-04-15       Impact factor: 5.157

5.  Outer membrane proteins responsible for the penetration of beta-lactams and quinolones in Pseudomonas aeruginosa.

Authors:  Y Yamano; T Nishikawa; Y Komatsu
Journal:  J Antimicrob Chemother       Date:  1990-08       Impact factor: 5.790

6.  New norfloxacin resistance gene in Pseudomonas aeruginosa PAO.

Authors:  H Fukuda; M Hosaka; K Hirai; S Iyobe
Journal:  Antimicrob Agents Chemother       Date:  1990-09       Impact factor: 5.191

7.  Transformation of Pseudomonas aeruginosa by electroporation.

Authors:  J M Diver; L E Bryan; P A Sokol
Journal:  Anal Biochem       Date:  1990-08-15       Impact factor: 3.365

Review 8.  Outer membrane proteins of Pseudomonas.

Authors:  R E Hancock; R Siehnel; N Martin
Journal:  Mol Microbiol       Date:  1990-07       Impact factor: 3.501

9.  Escherichia coli K-12 mutants resistant to nalidixic acid: genetic mapping and dominance studies.

Authors:  M W Hane; T H Wood
Journal:  J Bacteriol       Date:  1969-07       Impact factor: 3.490

10.  Broad-host-range gyrase A gene probe.

Authors:  N J Robillard
Journal:  Antimicrob Agents Chemother       Date:  1990-10       Impact factor: 5.191

View more
  13 in total

Review 1.  Quo vadis with bacterial resistance?

Authors:  J D Williams
Journal:  Drugs       Date:  1995       Impact factor: 9.546

Review 2.  Fluoroquinolones in the treatment of cystic fibrosis.

Authors:  N Høiby; S S Pedersen; T Jensen; N H Valerius; C Koch
Journal:  Drugs       Date:  1993       Impact factor: 9.546

3.  Genome macrorestriction analysis of diversity and variability of Pseudomonas aeruginosa strains infecting cystic fibrosis patients.

Authors:  M J Struelens; V Schwam; A Deplano; D Baran
Journal:  J Clin Microbiol       Date:  1993-09       Impact factor: 5.948

4.  Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus.

Authors:  J Fung-Tomc; B Kolek; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

5.  Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori.

Authors:  R A Moore; B Beckthold; S Wong; A Kureishi; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

Review 6.  Quinolone resistance in Pseudomonas aeruginosa and Staphylococcus aureus. Development during therapy and clinical significance.

Authors:  A Dalhoff
Journal:  Infection       Date:  1994       Impact factor: 3.553

7.  Development of multiple-antibiotic-resistant (Mar) mutants of Pseudomonas aeruginosa after serial exposure to fluoroquinolones.

Authors:  G G Zhanel; J A Karlowsky; M H Saunders; R J Davidson; D J Hoban; R E Hancock; I McLean; L E Nicolle
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

8.  Cloning and nucleotide sequence of Pseudomonas aeruginosa DNA gyrase gyrA gene from strain PAO1 and quinolone-resistant clinical isolates.

Authors:  A Kureishi; J M Diver; B Beckthold; T Schollaardt; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

9.  nfxC-type quinolone resistance in a clinical isolate of Pseudomonas aeruginosa.

Authors:  H Fukuda; M Hosaka; S Iyobe; N Gotoh; T Nishino; K Hirai
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

Review 10.  Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Authors:  R Davis; A Markham; J A Balfour
Journal:  Drugs       Date:  1996-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.